Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
Fiche publication
Date publication
mars 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Gross-Goupil M, Fourcade A, Blot E, Penel N, Negrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K
Lien Pubmed
Résumé
PURPOSE: To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C) or in combination with gemcitabine (CG). PATIENTS AND METHODS: Good prognosis was defined according to the GEFCAPI (Groupe d'Etude Francais des Carcinomes de site Primitif Inconnu) classification by PS (Performance Status)
Référence
Eur J Cancer. 2012 Mar;48(5):721-7